. home.aspx



Teva expands blood pressure drug recall in the US amid cancer fears

June 14, 2019 / Richard Staines

Teva has expanded a recall of losartan potassium tablets after tests revealed a potential human carcinogen in the blood pressure drug. The Israeli pharma earlier this week recalled six lots of the drug containing unacceptable levels of a nitrosamine impurity. This builds on a decision in April when Teva withdrew 35 lots after detecting the same impurity known as NMBA (N-Nitroso-N-methyl-4-aminobutyric acid). According to a recall notice shared by the FDA, Teva had sold bulk lots of the drug to California-based Golden State Medical Supply. The bottles were in sizes containing 30, 90 or 100 tablets. People affected by the recall should continue taking their drugs and ask a doctor or pharmacist about alternatives or replacements, the FDA said. This is because stopping the medication without replacement could cause more harm than continuing with the treatment course. Teva needs to maximise its revenues to pay off huge debts it incurred when it acquired Allergan’s generics business in...